Pharmaceuticals

Gene Therapy For Parkinson’s Disease Market Size Forecast: Revenue and CAGR by 2029

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Gene Therapy For Parkinson’s Disease Industry By The Forecast Year 2029?

The gene therapy for parkinson’s disease market has seen substantial growth over the past few years. This market is projected to expand from $0.51 billion in 2024 to $0.64 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 26.5%. Historically, this growth has been driven by factors such as the increasing incidence of Parkinson’s disease, a heightened need for personalized treatment options, greater understanding and acceptance of gene therapy, the enlargement of clinical trial infrastructure, and augmented investment in research for neurodegenerative conditions.

The gene therapy for parkinson’s disease market is poised for significant expansion in the coming years. This market is forecast to expand to $1.62 billion by 2029, achieving a compound annual growth rate (CAGR) of 26.1%. Factors driving this growth throughout the forecast period include the increasing uptake of viral vector-based therapies, heightened investments in gene therapy startups, enhanced government assistance for rare disease treatments, the expansion of research partnerships, and the advancing healthcare infrastructure in emerging markets. Key trends during the forecast period involve technological progress in viral delivery systems, novel developments in neurotrophic factor therapies, the creation of targeted gene-editing constructs, increased research and development investments, and evolving precision medicine approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

Which Drivers Are Impacting The Gene Therapy For Parkinson’s Disease Market?

The expanding focus on personalized medicine is anticipated to fuel the expansion of the gene therapy for Parkinson’s disease market in the future. Personalized medicine defines a medical methodology that customizes treatment and prevention tactics according to an individual’s unique genetic profile, way of life, and surroundings. The demand for personalized medicine is increasing, driven by the need for specific therapies that enhance treatment efficacy while reducing negative side effects. Within personalized medicine, gene therapy for Parkinson’s disease is utilized to provide customized genetic alterations that restore dopamine function and target disease mechanisms unique to each patient. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, announced that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, which represents a significant rise from the 6 approvals observed in 2022. Consequently, the heightened interest in personalized medicine is propelling the development of the gene therapy for Parkinson’s disease market.

What Are The Emerging Segments Gaining Attention In The Gene Therapy For Parkinson’s Disease Market?

The gene therapy for parkinson’s disease market covered in this report is segmented as

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegment:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

How Are Trends Influencing The Gene Therapy For Parkinson’s Disease Market?

Within the gene therapy for Parkinson’s disease market, leading companies are concentrating on creating more exact treatments, such as regenerative medicine advanced therapy. The aim is to improve neuronal survival, bring back dopamine function, and offer sustained disease-modifying advantages for individuals suffering from Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) represents a specific United States Food and Drug Administration (FDA) designation awarded to regenerative medicine products, including cell therapies, gene therapies, and tissue-engineered products, that aim to treat, modify, reverse, or cure serious or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy firm, launched AB-1005, an investigational AAV2-GDNF gene therapy that obtained FDA regenerative medicine advanced therapy (RMAT) designation. This designation, designed to accelerate the development and review process for promising therapies, was awarded based on data provided by AskBio, including clinical findings from its Phase Ib open-label, uncontrolled trial, showing AB-1005’s capacity to slow the progression of the disease and enhance motor function in Parkinson’s patients.

Who Are The Major Companies Operating In The Gene Therapy For Parkinson’s Disease Market?

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

Which Regional Markets Are Contributing Most To The Gene Therapy For Parkinson’s Disease Industry Expansion?

North America was the largest region in the gene therapy for parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene therapy for parkinson’s disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Gene Therapy For Parkinson’s Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28231&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2025, By The Business Research Company

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Anti Parkinson Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795